{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:45:58Z","timestamp":1790318758246,"version":"4.1.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Vast amounts of rapidly accumulating biological data related to cancer and a remarkable progress in the field of artificial intelligence (AI) have paved the way for precision oncology. Our recent contribution to this area of research is CancerOmicsNet, an AI-based system to predict the therapeutic effects of multitargeted kinase inhibitors across various cancers. This approach was previously demonstrated to outperform other deep learning methods, graph kernel models, molecular docking, and drug binding pocket matching.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>CancerOmicsNet integrates multiple heterogeneous data by utilizing a deep graph learning model with sophisticated attention propagation mechanisms to extract highly predictive features from cancer-specific networks. The AI-based system was devised to provide more accurate and robust predictions than data-driven therapeutic discovery using gene signature reversion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Selected CancerOmicsNet predictions obtained for \u201cunseen\u201d data are positively validated against the biomedical literature and by live-cell time course inhibition assays performed against breast, pancreatic, and prostate cancer cell lines. Encouragingly, six molecules exhibited dose-dependent antiproliferative activities, with pan-CDK inhibitor JNJ-7706621 and Src inhibitor PP1 being the most potent against the pancreatic cancer cell line Panc 04.03.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CancerOmicsNet is a promising AI-based platform to help guide the development of new approaches in precision oncology involving a variety of tumor types and therapeutics.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10293-0","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T11:05:06Z","timestamp":1669374306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors"],"prefix":"10.1186","volume":"22","author":[{"given":"Manali","family":"Singha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limeng","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent A.","family":"Stanfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifeanyi K.","family":"Uche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J. F.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin G.","family":"Kousoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ramanujam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Brylinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"10293_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1475-2867-10-11","volume":"10","author":"SS Knox","year":"2010","unstructured":"Knox SS. From 'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer. Cancer Cell Int. 2010;10:11.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"10293_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/cancers10030063","volume":"10","author":"J Cicenas","year":"2018","unstructured":"Cicenas J, et al. Kinases and cancer. Cancers (Basel). 2018;10(3):63.","journal-title":"Cancers (Basel)"},{"issue":"5600","key":"10293_CR3","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning G, et al. The protein kinase complement of the human genome. Science. 2002;298(5600):1912\u201334.","journal-title":"Science"},{"issue":"33","key":"10293_CR4","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1200\/JCO.2009.22.9054","volume":"27","author":"U McDermott","year":"2009","unstructured":"McDermott U, Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol. 2009;27(33):5650\u20139.","journal-title":"J Clin Oncol"},{"issue":"10","key":"10293_CR5","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1021\/ci100235n","volume":"50","author":"M Brylinski","year":"2010","unstructured":"Brylinski M, Skolnick J. Comprehensive structural and functional characterization of the human kinome by protein structure modeling and ligand virtual screening. J Chem Inf Model. 2010;50(10):1839\u201354.","journal-title":"J Chem Inf Model"},{"issue":"6","key":"10293_CR6","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1021\/mp1002976","volume":"7","author":"M Brylinski","year":"2010","unstructured":"Brylinski M, Skolnick J. Cross-reactivity virtual profiling of the human kinome by X-react (KIN): a chemical systems biology approach. Mol Pharm. 2010;7(6):2324\u201333.","journal-title":"Mol Pharm"},{"issue":"11","key":"10293_CR7","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/nbt.1990","volume":"29","author":"MI Davis","year":"2011","unstructured":"Davis MI, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29(11):1046\u201351.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10293_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar KS, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17(1):48.","journal-title":"Mol Cancer"},{"issue":"5","key":"10293_CR9","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/138920009788897975","volume":"10","author":"JT Hartmann","year":"2009","unstructured":"Hartmann JT, et al. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10(5):470\u201381.","journal-title":"Curr Drug Metab"},{"issue":"3","key":"10293_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jbi.2010.04.006","volume":"43","author":"X Yang","year":"2010","unstructured":"Yang X, et al. Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data. J Biomed Inform. 2010;43(3):376\u201384.","journal-title":"J Biomed Inform"},{"issue":"13","key":"10293_CR11","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1073\/pnas.1403080111","volume":"111","author":"TS Gujral","year":"2014","unstructured":"Gujral TS, Peshkin L, Kirschner MW. Exploiting polypharmacology for drug target deconvolution. Proc Natl Acad Sci U S A. 2014;111(13):5048\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10293_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrc2787","volume":"10","author":"ZA Knight","year":"2010","unstructured":"Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer. 2010;10(2):130\u20137.","journal-title":"Nat Rev Cancer"},{"key":"10293_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ejmech.2017.11.049","volume":"143","author":"X Ma","year":"2018","unstructured":"Ma X, Lv X, Zhang J. Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): an update of recent medicinal chemistry efforts. Eur J Med Chem. 2018;143:449\u201363.","journal-title":"Eur J Med Chem"},{"key":"10293_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-61779-337-0_7","volume":"795","author":"O Fedorov","year":"2012","unstructured":"Fedorov O, Niesen FH, Knapp S. Kinase inhibitor selectivity profiling using differential scanning fluorimetry. Methods Mol Biol. 2012;795:109\u201318.","journal-title":"Methods Mol Biol"},{"key":"10293_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-1-61779-337-0_11","volume":"795","author":"M Schirle","year":"2012","unstructured":"Schirle M, et al. Kinase inhibitor profiling using chemoproteomics. Methods Mol Biol. 2012;795:161\u201377.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"10293_CR16","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.celrep.2015.12.080","volume":"14","author":"KC Duong-Ly","year":"2016","unstructured":"Duong-Ly KC, et al. Kinase inhibitor profiling reveals unexpected opportunities to inhibit disease-associated mutant kinases. Cell Rep. 2016;14(4):772\u201381.","journal-title":"Cell Rep"},{"issue":"6","key":"10293_CR17","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.drudis.2015.01.002","volume":"20","author":"E Jacoby","year":"2015","unstructured":"Jacoby E, et al. Extending kinome coverage by analysis of kinase inhibitor broad profiling data. Drug Discov Today. 2015;20(6):652\u20138.","journal-title":"Drug Discov Today"},{"issue":"7","key":"10293_CR18","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.chembiol.2011.05.010","volume":"18","author":"CV Miduturu","year":"2011","unstructured":"Miduturu CV, et al. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. Chem Biol. 2011;18(7):868\u201379.","journal-title":"Chem Biol"},{"key":"10293_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1476-4598-3-9","volume":"3","author":"C Garnis","year":"2004","unstructured":"Garnis C, Buys TP, Lam WL. Genetic alteration and gene expression modulation during cancer progression. Mol Cancer. 2004;3:9.","journal-title":"Mol Cancer"},{"issue":"1","key":"10293_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57\u201370.","journal-title":"Cell"},{"issue":"3","key":"10293_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.lungcan.2007.08.037","volume":"59","author":"KC Lo","year":"2008","unstructured":"Lo KC, et al. Identification of genes involved in squamous cell carcinoma of the lung using synchronized data from DNA copy number and transcript expression profiling analysis. Lung Cancer. 2008;59(3):315\u201331.","journal-title":"Lung Cancer"},{"issue":"20","key":"10293_CR22","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJMra021902","volume":"347","author":"WC Hahn","year":"2002","unstructured":"Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med. 2002;347(20):1593\u2013603.","journal-title":"N Engl J Med"},{"issue":"23","key":"10293_CR23","first-page":"6744","volume":"60","author":"RS Ismail","year":"2000","unstructured":"Ismail RS, et al. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 2000;60(23):6744\u20139.","journal-title":"Cancer Res"},{"issue":"11","key":"10293_CR24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/nrc1214","volume":"3","author":"P Liang","year":"2003","unstructured":"Liang P, Pardee AB. Analysing differential gene expression in cancer. Nat Rev Cancer. 2003;3(11):869\u201376.","journal-title":"Nat Rev Cancer"},{"issue":"1\u20132","key":"10293_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000087513","volume":"112","author":"S Chen","year":"2006","unstructured":"Chen S, Zhu B, Yu L. In silico comparison of gene expression levels in ten human tumor types reveals candidate genes associated with carcinogenesis. Cytogenet Genome Res. 2006;112(1\u20132):53\u20139.","journal-title":"Cytogenet Genome Res"},{"key":"10293_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3389\/fgene.2019.00695","volume":"10","author":"JL Deng","year":"2019","unstructured":"Deng JL, Xu YH, Wang G. Identification of potential crucial genes and key pathways in breast Cancer using Bioinformatic analysis. Front Genet. 2019;10:695.","journal-title":"Front Genet"},{"key":"10293_CR27","doi-asserted-by":"publisher","first-page":"e919953","DOI":"10.12659\/MSM.919953","volume":"26","author":"JM Xue","year":"2020","unstructured":"Xue JM, et al. Comprehensive analysis of differential gene expression to identify common gene signatures in multiple cancers. Med Sci Monit. 2020;26:e919953.","journal-title":"Med Sci Monit"},{"issue":"10","key":"10293_CR28","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.molmed.2017.08.003","volume":"23","author":"D Senft","year":"2017","unstructured":"Senft D, et al. Precision oncology: the road ahead. Trends Mol Med. 2017;23(10):874\u201398.","journal-title":"Trends Mol Med"},{"key":"10293_CR29","unstructured":"Zhilong Jia XS, Shi J, Wang W, He K. Gene signature-based drug repositioning. In: Shailendra Saxena I, editor. Drug repurposing - molecular aspects and therapeutic applications. London: IntechOpen; 2021."},{"issue":"6","key":"10293_CR30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(6):1437\u20131452 e17.","journal-title":"Cell"},{"issue":"43","key":"10293_CR31","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5795","key":"10293_CR32","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"EDC Justin Lamb","year":"2006","unstructured":"Justin Lamb EDC, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929\u201335.","journal-title":"Science"},{"issue":"2","key":"10293_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1006\/bbrc.2001.4968","volume":"284","author":"R Hata","year":"2001","unstructured":"Hata R, et al. Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA microarray. Biochem Biophys Res Commun. 2001;284(2):310\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10293_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/15216540412331286002","volume":"56","author":"R Ricciarelli","year":"2004","unstructured":"Ricciarelli R, et al. Microarray analysis in Alzheimer's disease and normal aging. IUBMB Life. 2004;56(6):349\u201354.","journal-title":"IUBMB Life"},{"issue":"40","key":"10293_CR35","doi-asserted-by":"publisher","first-page":"14326","DOI":"10.1073\/pnas.0405941101","volume":"101","author":"BJ Blanchard","year":"2004","unstructured":"Blanchard BJ, et al. Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule. Proc Natl Acad Sci U S A. 2004;101(40):14326\u201332.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10293_CR36","doi-asserted-by":"publisher","first-page":"7371","DOI":"10.1021\/jo051096o","volume":"70","author":"EJ Hennessy","year":"2005","unstructured":"Hennessy EJ, Buchwald SL. Synthesis of 4,5-dianilinophthalimide and related analogues for potential treatment of Alzheimer's disease via palladium-catalyzed amination. J Organomet Chem. 2005;70(18):7371\u20135.","journal-title":"J Organomet Chem"},{"issue":"4","key":"10293_CR37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","volume":"10","author":"G Wei","year":"2006","unstructured":"Wei G, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006;10(4):331\u201342.","journal-title":"Cancer Cell"},{"issue":"16","key":"10293_CR38","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1093\/bioinformatics\/btz006","volume":"35","author":"J Chan","year":"2019","unstructured":"Chan J, et al. Breaking the paradigm: Dr insight empowers signature-free, enhanced drug repurposing. Bioinformatics. 2019;35(16):2818\u201326.","journal-title":"Bioinformatics"},{"issue":"7418","key":"10293_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas, N","year":"2012","unstructured":"Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370.","journal-title":"Nature"},{"issue":"4","key":"10293_CR40","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Cancer Genome Atlas Research, N","year":"2015","unstructured":"Cancer Genome Atlas Research, N. The molecular taxonomy of primary prostate Cancer. Cell. 2015;163(4):1011\u201325.","journal-title":"Cell"},{"issue":"5","key":"10293_CR41","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ccr.2005.10.001","volume":"8","author":"S Varambally","year":"2005","unstructured":"Varambally S, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell. 2005;8(5):393\u2013406.","journal-title":"Cancer Cell"},{"issue":"1","key":"10293_CR42","first-page":"51","volume":"9","author":"HR Chen","year":"2016","unstructured":"Chen HR, et al. A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer. BMC Med Genet. 2016;9(1):51.","journal-title":"BMC Med Genet"},{"issue":"1","key":"10293_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/carcin\/bgh308","volume":"26","author":"M Pignatelli","year":"2005","unstructured":"Pignatelli M, et al. 15-deoxy-Delta-12,14-prostaglandin J2 induces programmed cell death of breast cancer cells by a pleiotropic mechanism. Carcinogenesis. 2005;26(1):81\u201392.","journal-title":"Carcinogenesis"},{"issue":"4","key":"10293_CR44","first-page":"971","volume":"7","author":"DM Vigushin","year":"2001","unstructured":"Vigushin DM, et al. Trichostatin a is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001;7(4):971\u20136.","journal-title":"Clin Cancer Res"},{"key":"10293_CR45","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s12864-016-2737-8","volume":"17","author":"Z Jia","year":"2016","unstructured":"Jia Z, et al. Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and drug mode of action discovery. BMC Genomics. 2016;17:414.","journal-title":"BMC Genomics"},{"issue":"9","key":"10293_CR46","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nbt.4233","volume":"36","author":"M Wainberg","year":"2018","unstructured":"Wainberg M, et al. Deep learning in biomedicine. Nat Biotechnol. 2018;36(9):829\u201338.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10293_CR47","doi-asserted-by":"publisher","first-page":"bbac022","DOI":"10.1093\/bib\/bbac022","volume":"23","author":"T Jo","year":"2022","unstructured":"Jo T, et al. Deep learning-based identification of genetic variants: application to Alzheimer's disease classification. Brief Bioinform. 2022;23(2):bbac022.","journal-title":"Brief Bioinform"},{"issue":"2","key":"10293_CR48","doi-asserted-by":"publisher","first-page":"e1006718","DOI":"10.1371\/journal.pcbi.1006718","volume":"15","author":"L Pu","year":"2019","unstructured":"Pu L, et al. DeepDrug3D: classification of ligand-binding pockets in proteins with a convolutional neural network. PLoS Comput Biol. 2019;15(2):e1006718.","journal-title":"PLoS Comput Biol"},{"issue":"10","key":"10293_CR49","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1093\/bioinformatics\/btaa094","volume":"36","author":"W Shi","year":"2020","unstructured":"Shi W, et al. BionoiNet: ligand-binding site classification with off-the-shelf deep neural network. Bioinformatics. 2020;36(10):3077\u201383.","journal-title":"Bioinformatics"},{"key":"10293_CR50","doi-asserted-by":"publisher","first-page":"837715","DOI":"10.3389\/fphar.2022.837715","volume":"13","author":"W Shi","year":"2022","unstructured":"Shi W, et al. Pocket2Drug: an encoder-decoder deep neural network for the target-based drug design. Front Pharmacol. 2022;13:837715.","journal-title":"Front Pharmacol"},{"issue":"1","key":"10293_CR51","first-page":"58","volume":"13","author":"G Liu","year":"2021","unstructured":"Liu G, et al. GraphDTI: a robust deep learning predictor of drug-target interactions from multiple heterogeneous data. Aust J Chem. 2021;13(1):58.","journal-title":"Aust J Chem"},{"issue":"1","key":"10293_CR52","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41467-021-21330-0","volume":"12","author":"S Rodriguez","year":"2021","unstructured":"Rodriguez S, et al. Machine learning identifies candidates for drug repurposing in Alzheimer's disease. Nat Commun. 2021;12(1):1033.","journal-title":"Nat Commun"},{"issue":"1","key":"10293_CR53","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s42256-020-00276-w","volume":"3","author":"R Liu","year":"2021","unstructured":"Liu R, Wei L, Zhang P. A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data. Nat Mach Intell. 2021;3(1):68\u201375.","journal-title":"Nat Mach Intell"},{"issue":"1","key":"10293_CR54","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/bib\/bbz171","volume":"22","author":"D Baptista","year":"2021","unstructured":"Baptista D, Ferreira PG, Rocha M. Deep learning for drug response prediction in cancer. Brief Bioinform. 2021;22(1):360\u201379.","journal-title":"Brief Bioinform"},{"issue":"11","key":"10293_CR55","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1016\/j.celrep.2019.11.017","volume":"29","author":"T Sakellaropoulos","year":"2019","unstructured":"Sakellaropoulos T, et al. A deep learning framework for predicting response to therapy in Cancer. Cell Rep. 2019;29(11):3367\u20133373 e4.","journal-title":"Cell Rep"},{"issue":"5","key":"10293_CR56","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.ccell.2020.09.014","volume":"38","author":"BM Kuenzi","year":"2020","unstructured":"Kuenzi BM, et al. Predicting drug response and synergy using a deep learning model of human Cancer cells. Cancer Cell. 2020;38(5):672\u2013684 e6.","journal-title":"Cancer Cell"},{"key":"10293_CR57","doi-asserted-by":"publisher","first-page":"639349","DOI":"10.3389\/fbinf.2021.639349","volume":"1","author":"H Zhang","year":"2021","unstructured":"Zhang H, Chen Y, Li F. Predicting anticancer drug response with deep learning constrained by signaling pathways. Front Bioinform. 2021;1:639349.","journal-title":"Front Bioinform"},{"issue":"8","key":"10293_CR58","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1021\/acs.jcim.1c00706","volume":"61","author":"I Jin","year":"2021","unstructured":"Jin I, Nam H. HiDRA: hierarchical network for drug response prediction with attention. J Chem Inf Model. 2021;61(8):3858\u201367.","journal-title":"J Chem Inf Model"},{"key":"10293_CR59","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.semcdb.2016.07.005","volume":"58","author":"P Csermely","year":"2016","unstructured":"Csermely P, Korcsmaros T, Nussinov R. Intracellular and intercellular signaling networks in cancer initiation, development and precision anti-cancer therapy: RAS acts as contextual signaling hub. Semin Cell Dev Biol. 2016;58:55\u20139.","journal-title":"Semin Cell Dev Biol"},{"key":"10293_CR60","doi-asserted-by":"publisher","first-page":"695","DOI":"10.18632\/oncotarget.28234","volume":"13","author":"L Pu","year":"2022","unstructured":"Pu L, et al. CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling. Oncotarget. 2022;13:695\u2013706.","journal-title":"Oncotarget"},{"issue":"1","key":"10293_CR61","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41540-022-00226-9","volume":"8","author":"L Pu","year":"2022","unstructured":"Pu L, et al. An integrated network representation of multiple cancer-specific data for graph-based machine learning. NPJ Syst Biol Appl. 2022;8(1):14.","journal-title":"NPJ Syst Biol Appl"},{"issue":"6","key":"10293_CR62","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner M, et al. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Methods. 2016;13(6):521\u20137.","journal-title":"Nat Methods"},{"issue":"1","key":"10293_CR63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cels.2017.11.001","volume":"6","author":"AB Keenan","year":"2018","unstructured":"Keenan AB, et al. The library of integrated network-based cellular signatures NIH program: system-level cataloging of human cells response to perturbations. Cell Syst. 2018;6(1):13\u201324.","journal-title":"Cell Syst"},{"issue":"7391","key":"10293_CR64","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, et al. The Cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603\u20137.","journal-title":"Nature"},{"issue":"1\u20133","key":"10293_CR65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski CA, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1\u20133):3\u201326.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"10293_CR66","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","volume":"55","author":"T Sterling","year":"2015","unstructured":"Sterling T, Irwin JJ. ZINC 15--ligand discovery for everyone. J Chem Inf Model. 2015;55(11):2324\u201337.","journal-title":"J Chem Inf Model"},{"key":"10293_CR67","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/npjsba.2016.15","volume":"2","author":"Q Duan","year":"2016","unstructured":"Duan Q, et al. L1000CDS(2): LINCS L1000 characteristic direction signatures search engine. NPJ Syst Biol Appl. 2016;2:16015.","journal-title":"NPJ Syst Biol Appl"},{"issue":"4","key":"10293_CR68","first-page":"35","volume":"24","author":"A Singhal","year":"2010","unstructured":"Singhal A. Modern information retrieval: a brief overview. Bulletin IEEE Comp Soc Tech Commit Data Engr. 2010;24(4):35\u201343.","journal-title":"Bulletin IEEE Comp Soc Tech Commit Data Engr"},{"key":"10293_CR69","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ymeth.2014.11.020","volume":"74","author":"S Pletscher-Frankild","year":"2015","unstructured":"Pletscher-Frankild S, et al. DISEASES: text mining and data integration of disease-gene associations. Methods. 2015;74:83\u20139.","journal-title":"Methods"},{"issue":"D1","key":"10293_CR70","doi-asserted-by":"publisher","first-page":"D833","DOI":"10.1093\/nar\/gkw943","volume":"45","author":"J Pinero","year":"2017","unstructured":"Pinero J, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 2017;45(D1):D833\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10293_CR71","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/cmdc.201700180","volume":"13","author":"FA Sorgenfrei","year":"2018","unstructured":"Sorgenfrei FA, Fulle S, Merget B. Kinome-wide profiling prediction of small molecules. ChemMedChem. 2018;13(6):495\u20139.","journal-title":"ChemMedChem"},{"issue":"D1","key":"10293_CR72","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607\u201313.","journal-title":"Nucleic Acids Res"},{"key":"10293_CR73","unstructured":"Xu K, et al. Representation Learning on Graphs with Jumping Knowledge Networks. arXiv. 2018:1806.03536."},{"key":"10293_CR74","unstructured":"Vinyals O, Bengio S, Kudlur M. Order matters: sequence to sequence for sets. arXiv. 2015:1511.06391."},{"key":"10293_CR75","doi-asserted-by":"publisher","first-page":"vi42","DOI":"10.1093\/annonc\/mdm223","volume":"18 Suppl 6","author":"A Olivieri","year":"2007","unstructured":"Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol. 2007;18 Suppl 6:vi42\u20136.","journal-title":"Ann Oncol"},{"key":"10293_CR76","first-page":"5415","volume":"67","author":"C Pichot","year":"2007","unstructured":"Pichot C, et al. Dasatinib blocks the growth, migration, and invasion of breast cancer cells through inhibition of Src family kinases. Cancer Res. 2007;67:5415\u20135.","journal-title":"Cancer Res"},{"issue":"6","key":"10293_CR77","first-page":"394","volume":"13","author":"RA Mesa","year":"2010","unstructured":"Mesa RA. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs. 2010;13(6):394\u2013403.","journal-title":"IDrugs"},{"key":"10293_CR78","volume-title":"Ruxolitinib for the treatment of solid organ transplant recipients with advanced skin squamous cell Cancer","author":"Institute, N.C","year":"2019","unstructured":"Institute, N.C Ruxolitinib for the treatment of solid organ transplant recipients with advanced skin squamous cell Cancer. 2019; Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/clinical-trials\/search\/v?id=NCI-2021-05547&r=1."},{"key":"10293_CR79","first-page":"2579","volume":"9","author":"LJP van der Maaten","year":"2008","unstructured":"van der Maaten LJP, Hinton GE. Visualizing high-dimensional data using t-SNE. J Mach Learn Res. 2008;9:2579\u2013605.","journal-title":"J Mach Learn Res"},{"issue":"24","key":"10293_CR80","doi-asserted-by":"publisher","first-page":"10797","DOI":"10.1021\/jm301085w","volume":"55","author":"F Musumeci","year":"2012","unstructured":"Musumeci F, et al. Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. J Med Chem. 2012;55(24):10797\u2013822.","journal-title":"J Med Chem"},{"issue":"17","key":"10293_CR81","doi-asserted-by":"publisher","first-page":"8715","DOI":"10.1158\/0008-5472.CAN-05-4665","volume":"66","author":"A Polverino","year":"2006","unstructured":"Polverino A, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006;66(17):8715\u201321.","journal-title":"Cancer Res"},{"key":"10293_CR82","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1476-4598-11-70","volume":"11","author":"A Coxon","year":"2012","unstructured":"Coxon A, et al. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer. 2012;11:70.","journal-title":"Mol Cancer"},{"issue":"2","key":"10293_CR83","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","volume":"29","author":"A Bairoch","year":"2018","unstructured":"Bairoch A. The Cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29(2):25\u201338.","journal-title":"J Biomol Tech"},{"issue":"1","key":"10293_CR84","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1078-0432.CCR-08-1155","volume":"15","author":"A Coxon","year":"2009","unstructured":"Coxon A, et al. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and kit receptors. Clin Cancer Res. 2009;15(1):110\u20138.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10293_CR85","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/1759-7714.12136","volume":"5","author":"HL Zhao","year":"2014","unstructured":"Zhao HL, et al. Overview of fundamental study of pazopanib in cancer. Thorac Cancer. 2014;5(6):487\u201393.","journal-title":"Thorac Cancer"},{"issue":"4","key":"10293_CR86","first-page":"443","volume":"71","author":"SV Keisner","year":"2011","unstructured":"Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011;71(4):443\u201354.","journal-title":"Drugs"},{"issue":"4","key":"10293_CR87","first-page":"5819","volume":"18","author":"D Canter","year":"2011","unstructured":"Canter D, et al. Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. Can J Urol. 2011;18(4):5819\u201325.","journal-title":"Can J Urol"},{"key":"10293_CR88","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3389\/fonc.2019.01202","volume":"9","author":"T Di Desidero","year":"2019","unstructured":"Di Desidero T, et al. Effects of pazopanib monotherapy vs. pazopanib and topotecan combination on anaplastic thyroid cancer cells. Front Oncol. 2019;9:1202.","journal-title":"Front Oncol"},{"issue":"3","key":"10293_CR89","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1517\/13543781003598862","volume":"19","author":"M Shabbir","year":"2010","unstructured":"Shabbir M, Stuart R. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside. Expert Opin Investig Drugs. 2010;19(3):427\u201336.","journal-title":"Expert Opin Investig Drugs"},{"issue":"10","key":"10293_CR90","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1182\/blood-2006-04-015560","volume":"108","author":"S Knapper","year":"2006","unstructured":"Knapper S, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006;108(10):3262\u201370.","journal-title":"Blood"},{"issue":"12","key":"10293_CR91","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1182\/blood-2007-04-083402","volume":"111","author":"EO Hexner","year":"2008","unstructured":"Hexner EO, et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2\/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood. 2008;111(12):5663\u201371.","journal-title":"Blood"},{"issue":"4","key":"10293_CR92","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/(SICI)1097-0215(19970807)72:4<673::AID-IJC20>3.0.CO;2-B","volume":"72","author":"AM Camoratto","year":"1997","unstructured":"Camoratto AM, et al. CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity. Int J Cancer. 1997;72(4):673\u20139.","journal-title":"Int J Cancer"},{"key":"10293_CR93","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/j.1749-6632.1999.tb09530.x","volume":"880","author":"SJ Miknyoczki","year":"1999","unstructured":"Miknyoczki SJ, et al. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. Ann N Y Acad Sci. 1999;880:252\u201362.","journal-title":"Ann N Y Acad Sci"},{"issue":"19","key":"10293_CR94","doi-asserted-by":"publisher","first-page":"9038","DOI":"10.1158\/0008-5472.CAN-05-0882","volume":"65","author":"S Emanuel","year":"2005","unstructured":"Emanuel S, et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res. 2005;65(19):9038\u201346.","journal-title":"Cancer Res"},{"issue":"14","key":"10293_CR95","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1016\/j.bmcl.2006.04.071","volume":"16","author":"S Huang","year":"2006","unstructured":"Huang S, et al. Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006;16(14):3639\u201341.","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10293_CR96","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1074\/jbc.271.2.695","volume":"271","author":"JH Hanke","year":"1996","unstructured":"Hanke JH, et al. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem. 1996;271(2):695\u2013701.","journal-title":"J Biol Chem"},{"issue":"7","key":"10293_CR97","doi-asserted-by":"publisher","first-page":"4847","DOI":"10.1074\/jbc.M209321200","volume":"278","author":"L Tatton","year":"2003","unstructured":"Tatton L, et al. The Src-selective kinase inhibitor PP1 also inhibits kit and Bcr-Abl tyrosine kinases. J Biol Chem. 2003;278(7):4847\u201353.","journal-title":"J Biol Chem"},{"issue":"10","key":"10293_CR98","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1111\/j.1538-7836.2012.04898.x","volume":"10","author":"S Nylander","year":"2012","unstructured":"Nylander S, et al. Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. J Thromb Haemost. 2012;10(10):2127\u201336.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10293_CR99","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/2159-8290.CD-12-0003","volume":"2","author":"J Ni","year":"2012","unstructured":"Ni J, et al. Functional characterization of an isoform-selective inhibitor of PI3K-p110beta as a potential anticancer agent. Cancer Discov. 2012;2(5):425\u201333.","journal-title":"Cancer Discov"},{"issue":"42","key":"10293_CR100","doi-asserted-by":"publisher","first-page":"11865","DOI":"10.1073\/pnas.1609019113","volume":"113","author":"EC Lin","year":"2016","unstructured":"Lin EC, et al. ERK5 kinase activity is dispensable for cellular immune response and proliferation. Proc Natl Acad Sci U S A. 2016;113(42):11865\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10293_CR101","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1021\/ml100304b","volume":"2","author":"X Deng","year":"2011","unstructured":"Deng X, et al. Discovery of a benzo [e]pyrimido-[5,4-b][1,4] diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1. ACS Med Chem Lett. 2011;2(3):195\u2013200.","journal-title":"ACS Med Chem Lett"},{"issue":"44","key":"10293_CR102","doi-asserted-by":"publisher","first-page":"16078","DOI":"10.1073\/pnas.0502000102","volume":"102","author":"JG Conway","year":"2005","unstructured":"Conway JG, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A. 2005;102(44):16078\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10293_CR103","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1158\/1535-7163.MCT-08-1200","volume":"8","author":"FI Raynaud","year":"2009","unstructured":"Raynaud FI, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 2009;8(7):1725\u201338.","journal-title":"Mol Cancer Ther"},{"issue":"40","key":"10293_CR104","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1038\/onc.2009.215","volume":"28","author":"MA Westhoff","year":"2009","unstructured":"Westhoff MA, et al. The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene. 2009;28(40):3586\u201396.","journal-title":"Oncogene"},{"issue":"1","key":"10293_CR105","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/bib\/bbv020","volume":"17","author":"J Li","year":"2016","unstructured":"Li J, et al. A survey of current trends in computational drug repositioning. Brief Bioinform. 2016;17(1):2\u201312.","journal-title":"Brief Bioinform"},{"key":"10293_CR106","doi-asserted-by":"publisher","first-page":"e71880","DOI":"10.7554\/eLife.71880","volume":"11","author":"C Yang","year":"2022","unstructured":"Yang C, et al. A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. Elife. 2022;11:e71880.","journal-title":"Elife"},{"key":"10293_CR107","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/ncomms16022","volume":"8","author":"B Chen","year":"2017","unstructured":"Chen B, et al. Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets. Nat Commun. 2017;8:16022.","journal-title":"Nat Commun"},{"issue":"2","key":"10293_CR108","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1208\/s12248-012-9447-1","volume":"15","author":"JP Bai","year":"2013","unstructured":"Bai JP, et al. Strategic applications of gene expression: from drug discovery\/development to bedside. AAPS J. 2013;15(2):427\u201337.","journal-title":"AAPS J"},{"issue":"20","key":"10293_CR109","doi-asserted-by":"publisher","first-page":"5690","DOI":"10.1158\/0008-5472.CAN-13-3540","volume":"74","author":"V van Noort","year":"2014","unstructured":"van Noort V, et al. Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling. Cancer Res. 2014;74(20):5690\u20139.","journal-title":"Cancer Res"},{"issue":"11","key":"10293_CR110","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/1947601912440575","volume":"2","author":"RJ Tallarida","year":"2011","unstructured":"Tallarida RJ. Quantitative methods for assessing drug synergism. Genes Cancer. 2011;2(11):1003\u20138.","journal-title":"Genes Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10293-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10293-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10293-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T22:27:10Z","timestamp":1669415230000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10293-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10293"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10293-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"20 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interests exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1211"}}